02:07 PM EDT, 03/11/2025 (MT Newswires) -- Gilead Sciences ( GILD ) said Tuesday that two different once-yearly formulations of lenacapavir for HIV prevention were found to be safe and well tolerated in an ongoing study.

The company said it presented the first data from its ongoing phase 1 study of the formulations at a medical conference and also published the results in The Lancet.

The data showed that the formulations reached and maintained blood levels above those associated with preventing HIV in earlier phase 3 trials that studied a twice-yearly version of lenacapavir.

The data will support the future development of once-yearly lenacapavir, for which Gilead plans to launch a phase 3 study in H2, the company said.

Gilead shares were down 2% in recent trading.

Price: 114.77, Change: -2.44, Percent Change: -2.08